Alzheimer's Weekly

Options

» Caregivers
» Fight the Fight
» Items of Interest
» Prevention
» Research
» Treatment
» Weekly Videos

Newsletter

Research

Bapineuzumab Moves Forwards, Dimebon Falls Back

VIDEO + IN-DEPTH ARTICLE

It has been a week of victories and defeats in the lab. The highly promising drug bapineuzumab visibly reduced amyloid in human clinical trials by 25%. That's exciting because it is a real improvement that was seen and measured. On the downside, Dimebon's clinical trial results were particularly disappointing in light of the Alzheimer's community's high expectations for it.

Uncle Sam Combats Alzheimer's

New U.S. government legislation aims to "coordinate a strong and sustained federal research effort" against dementias such as Alzheimer's.

SWAN: Semantic Web Applications in Neuromedicine

Every week, researchers are publishing over 100 papers on dementias such as Alzheimer's. SWAN stands for "Semantic Web Applications in Neuromedicine." Read how this large internet collaboration is organizing our community's exploding body of scientific knowledge.

VIDEO & IN-DEPTH ARTICLE

Dr. Karl Kieburtz, lead author of a new Dimebon study, says that the "results are encouraging and show, for the first time, a statistically significant benefit in terms of improved cognitive function in patients with Huntington's disease."

VIDEO + TRANSCRIPT

The Center for Neurodegenerative Disease Research at U of P is unique. There is tremendous crossover of neurodegenerative diseases like frontotemporal dementia, Alzheimer's, ALS and Parkinsons. So unlike many labs that focus on one disease, CNDR studies these together as a group that could effect your memory, your emotions and your movement.

VIDEO & IN DEPTH ARTICLE

"We have shown that davunetide is the most advanced tau therapy in the world," stated Gordon McCauley of Allon Therapeutics. Tau is a brain protein. Tau impairment is clearly involved in the cause of Alzheimer's, PSP and other frontotemporal dementias.

VIDEO + TRANSCRIPT

Chlamydia pneumoniae is a respiratory pathogen and appears to be a potential Alzheimer's trigger. This discovery is driving a passionate collaboration between researchers and their students at PCOM. Watch this inspiring video in search of new treatments.

Souvenaid Shows Mild Benefits

Axona was the first Alzheimer's-medical-food. Building on its success, MIT has developed a new and very different formulation to improve memory in dementias such as Alzheimer's. They hope to shortly introduce it as another medical food.

A researcher studies scans from the Leptin study.

VIDEO + ARTICLE

New brain scan techniques are detecting oncoming dementias such as Alzheimer's even before clear symptoms appear. Learn how they could lead to better treatments.

Amyloid Attacks Synapses

Amyloid beta is the most popular yet controversial suspect behind dementias like Alzheimer's. University of California researchers are unraveling how it does much of its damage.